The Party Committee of Pharmaceutical Company Organized Learning to Celebrate the 40th Anniversary of Reform and Opening-up
Release time:
2020-08-14
Pharmaceutical Company organized a study to celebrate the 3rd anniversary of the reform and opening up 40# speech
News from our newspaper 12# September 19 afternoon, the Party Committee of Jianfeng Pharmaceutical Company organized the secretaries of all grass-roots party organizations to earnestly study and understand the spirit of General Secretary Xi Jinping's important speech at the celebration of the 13th anniversary of the reform and opening up 40 .
40 The General Assembly 12 18 was held in the Great Hall of the People on the morning of December 22. Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission attended the conference and delivered an important speech. He reviewed the magnificent and glorious course of reform and opening up 40 years, summarized the great achievements of reform and opening up, and proposed to continue reform and opening up in the new era. Push forward the goal requirements. At the study meeting, Jin Huazhong, secretary of the party Committee of the pharmaceutical company, led the general secretary of the whole literature study to give a speech, explaining the hot spots and details of media attention, and shared the historical context, historical position, overall evaluation, great achievements and valuable experience of the 28th anniversary of China's reform and opening up 40# by means of PPT . He said that General Secretary Xi's speech is a programmatic document of Marxism, a new declaration and a new mobilization order for reform and opening up in the new era. It is of great practical significance and far-reaching historical significance to encourage and encourage the whole Party and the people of all ethnic groups to continue to push forward reform and opening up in the new era, and to make unremitting efforts to realize the "two centenary" goals and realize the Chinese dream of the great rejuvenation of the Chinese nation, it will also have a huge impact on the reform and development of enterprises. The participants exchanged their learning experiences based on the actual conditions of their respective companies. They agreed that for pharmaceutical companies, they are currently in a critical period of corporate reform and development. Risks and opportunities converge, challenges and advantages coexist. Taking advantage of the east wind of reform and opening up, Jianfeng Pharmaceutical Industry must take advantage of the trend and advance bravely. It must not forget its original intention to continuously strengthen innovation, strengthen technological transformation, and improve the quality of employees, the trickle of gathering enterprises has merged into the torrent of national reform and opening up, making enterprises invincible in the fierce competition. Everyone also talked about the changes brought about by the reform and opening up to individuals and the sense of gain in the reform process. The Party Committee of
Pharmaceutical Company requires all grass-roots party organizations to organize all Party members to earnestly study the important speech of General Secretary Xi Jinping at the 36th anniversary conference celebrating the reform and opening up
2018 . The attending secretaries also discussed the work of the party organization in the new year. (This correspondent)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page